Skip to content
drillr.ai
Sign up

JNJ

JOHNSON & JOHNSON

NYSE · Healthcare · Drug Manufacturers - General · US

$269.99
−0.09%
Ask drillr

  • Sep 18, 2026, 01:58 UTC

    Johnson & Johnson's Abiomed unit is removing every Automated Impella Controller worldwide to replace parts linked to failures associated with 37 serious injuries and three deaths, per an FDA early alert.

    Source:

  • Sep 17, 2026, 22:45 UTC

    Johnson & Johnson (JNJ) shares rose 1.1% to close at $270.22 in the most recent trading session.

    Source:

  • Sep 17, 2026, 21:18 UTC

    PepsiCo appointed Joaquin Duato, Johnson & Johnson's Chairman and CEO, as an independent member of its Board effective December 1, 2026.

  • Sep 16, 2026, 11:49 UTC

    Johnson & Johnson announced the launch in China of Rybrevant (amivantamab) subcutaneous injection, in combination with Lazcluze (lazertinib), for first-line treatment of adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 19 deletions or exon 21 L858R substitution mutations.

    Source:

  • Sep 15, 2026, 14:15 UTC

    Nebraska counties and cities received shares of nationwide opioid settlements totaling more than $50 billion, with Nebraska's portion exceeding $150 million over 18 years, and at least nine counties and cities spent at least $88,800 of those funds on law enforcement tools including Flock Safety license plate reader cameras.

    Source:

  • Sep 15, 2026, 04:08 UTC

    Defensive stocks including Johnson & Johnson, Eli Lilly, Kimberly-Clark, Costco, CrowdStrike and Palo Alto Networks rallied on Monday as Wall Street rotated out of AI infrastructure names, while Meta Platforms, Alphabet and Microsoft also advanced.

    Source:

  • Sep 15, 2026, 03:00 UTC

    Johnson & Johnson announced new Phase 2b COPERNICUS study results at WCLC 2026 showing low rates of treatment-related events with subcutaneous RYBREVANT FASPRO plus LAZCLUZE in previously untreated advanced EGFR-mutated non-small cell lung cancer.

    Source:

  • Sep 14, 2026, 20:38 UTC

    Contineum Therapeutics announced that an experimental depression drug developed with Johnson & Johnson failed to meet the main goal of a mid-stage clinical trial.

    Source:

  • Sep 14, 2026, 01:58 UTC

    Apollo Global Management is reportedly in talks to acquire Johnson & Johnson's DePuy Synthes orthopedics business for around $20 billion.

    Source:

  • Sep 14, 2026, 01:46 UTC

    Johnson & Johnson announced that RYBREVANT combined with chemotherapy achieved the longest reported median overall survival in EGFR exon 20 insertion-mutated non-small cell lung cancer.

    Source:

  • Sep 11, 2026, 22:25 UTC

    Apollo is reportedly in talks to acquire Johnson & Johnson's orthopedics business unit.

    Source:

  • Sep 11, 2026, 03:55 UTC

    In US after-hours trading on September 11, 2026, most pharmaceutical and biotech stocks rose, with Eli Lilly up 0.03%, Johnson & Johnson up 0.32%, Merck up 0.09%, Novartis up 0.14%, AstraZeneca up 0.38% and Novo Nordisk up 0.11%.

    Source:

  • Sep 10, 2026, 15:15 UTC

    NICE issued Final Draft Guidance recommending Johnson & Johnson's Imbruvica (ibrutinib) with R-CHOP, alternating with R-DHAP or R-DHAOx followed by ibrutinib monotherapy, for adults with previously untreated mantle cell lymphoma suitable for autologous stem cell transplant in the UK.

    Source:

  • Sep 10, 2026, 11:45 UTC

    Johnson & Johnson received CE Marking for its ACUVUE OASYS MAX 2-Week reusable contact lenses.

    Source:

  • Sep 9, 2026, 23:30 UTC

    Johnson & Johnson secured Chinese regulatory approval for Icotyde, its once-daily oral treatment for moderate-to-severe plaque psoriasis, expanding its psoriasis portfolio in China.

    Source:

  • Sep 9, 2026, 15:51 UTC

    Johnson & Johnson announced plans to separate its orthopedics business in mid-2027, as part of a broader MedTech reset to focus on cardiovascular and other growth areas.

    Source:

  • Sep 9, 2026, 03:30 UTC

    The APEC Business Advisory Council upgraded its Supply Chain Resilience Toolkit, adding an AI-enabled tariff tool and expanding it to seven languages, to help small businesses manage supply chain risks and trade compliance.

    Source:

  • Sep 8, 2026, 20:05 UTC

    Protagonist Therapeutics announced a share repurchase program authorizing up to $300 million of its common stock, funded from cash and collaboration payments.

    Source:

  • Sep 1, 2026, 21:45 UTC

    Johnson & Johnson shares rose 2.01% to $271.19 in the latest session, outperforming the S&P 500's 0.71% decline.

    Source:

  • Aug 27, 2026, 08:33 UTC

    Johnson & Johnson announced that its IL-23 receptor antagonist oral peptide drug Ateya (ecopipitant hydrochloride tablets) received approval from China's National Medical Products Administration for treating moderate-to-severe plaque psoriasis in adults and children aged 12 and above weighing at least 40 kg.

    Source:

  • Aug 25, 2026, 00:00 UTC

    Parabilis Medicines, Inc. appointed Craig Tendler, M.D., as a director, effective August 22, 2026, and granted him a stock option to purchase 20,294 shares of common stock at an exercise price of $39.36 per share.

  • Aug 24, 2026, 22:33 UTC

    The U.S. Food and Drug Administration expanded approval for Johnson & Johnson's drug to treat a rare blood disorder, announced by the company on Monday.

    Source:

  • Aug 24, 2026, 16:20 UTC

    A Louisiana jury awarded a $10 million verdict in a mesothelioma case against Johnson & Johnson, brought by the family of Lynne Roy over talc exposure.

    Source:

  • Aug 22, 2026, 04:15 UTC

    A US judge in Virginia ruled in favor of three researchers in a defamation lawsuit filed by Johnson & Johnson over a 2020 scientific article linking talc to cancer.

    Source:

  • Aug 21, 2026, 16:46 UTC

    Johnson & Johnson received FDA 510(k) clearance for the MONARCH QUEST 3 update, adding AI-powered planning, navigation, and imaging upgrades for robotic bronchoscopy.

    Source:

  • Aug 20, 2026, 07:24 UTC

    Benjamin Edwards Inc. increased its stake in Johnson & Johnson by 21.8% during the second quarter of 2026, purchasing an additional 28,700 shares, according to its Form 13F filing.

    Source:

  • Aug 19, 2026, 19:38 UTC

    Biopharma stocks including AbbVie, Amgen, Eli Lilly, Johnson & Johnson, and Merck rallied on Wednesday, with Merck jumping 12.4%.

    Source:

  • Aug 9, 2026, 06:00 UTC

    Johnson & Johnson offered $5.5 billion to settle over 70,000 outstanding talc-related cancer lawsuits.

    Source:

  • Aug 3, 2026, 00:00 UTC

    Lipocine Inc. appointed Michael J. Grissinger as a director, effective August 3, 2026, with an initial stock option grant to purchase 2,000 shares of common stock.

    Source:
Page 1Next →